Invivo therapeutics holdings corp. (NVIV)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Operating expenses:
Research and development

5,602

4,931

11,083

12,557

10,058

10,273

10,533

6,376

4,102

1,673

General and administrative

5,895

7,836

13,510

11,506

12,340

7,566

8,472

6,403

4,555

1,724

Total operating expenses

11,497

12,767

24,593

24,063

22,398

17,839

19,005

12,779

8,658

3,397

Operating loss

-11,497

-12,767

-24,593

-24,063

-22,398

-17,839

-19,005

-12,779

-8,658

-3,397

Other income / (expense):
Interest income

-

-

-

187

60

5

15

35

8

3

Interest expense

-

-

-

155

172

136

130

72

12

-

(Decrease) increase in the fair value of the warrants

-

-

-

-

-

-

765

-

-

-

Interest income

254

206

115

-

-

-

-

-

-

-564

Warrant modification expense

666

765

-

-

-

-

-

-

-

-

Other income

-

-

-

625

-10,916

-507

-19,751

17,443

-26,069

-

Derivatives loss

-

-11,400

-2,267

593

-10,804

-376

-18,871

17,480

-26,065

-3,952

Other income

79

1,303

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-18,346

-

-

-

-

Other income / (expense), net

-333

-10,656

-2,152

-

-

-

-

-

-

-4,513

Net loss

-11,830

-23,423

-26,745

-23,438

-33,314

-

-38,756

4,664

-34,728

-7,910

Net loss per share, basic and diluted (in dollars per share)

-35.28

-140.81

-20.29

-0.76

-1.26

-0.83

-2.10

-

-

-0.24

Weighted average number of common shares outstanding, basic and diluted (In Shares)

335

166

1,318

31,025

26,461

22,080

18,497

-

-

-

Net loss

-11,830

-23,423

-26,745

-23,438

-33,314

-

-

-

-

-

Net loss

-

-

-

-

-

-18,346

-

-

-

-

Comprehensive loss

-

-

-26,745

-23,438

-33,314

-

-

-

-

-

Net loss per share, basic (in dollars per share)

-

-

-

-

-

-

-

0.07

-0.67

-

Net loss per share, diluted (in dollars per share)

-

-

-

-

-

-

-

0.06

-0.67

-

Weighted average number of common shares outstanding, basic (in shares)

-

-

-

-

-

-

-

63,226

51,894

-

Weighted average number of common shares outstanding, diluted (in shares)

-

-

-

-

-

-

-

71,919

51,894

-

Weighted average number of common shares outstanding, basic and diluted

-

-

-

-

-

-

-

-

-

33,367